Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 299

    1.

    Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials.

    Di Maio M, Signoriello S, Morabito A, Rossi A, Maione P, Piantedosi F, Bilancia D, Cigolari S, Barbera S, Gebbia V, Daniele B, Robbiati SF, Illiano A, Ceribelli A, Carrozza F, Favaretto A, Piazza E, Piccirillo MC, Daniele G, Giordano P, Costanzo R, Sandomenico C, Rocco G, Gallo C, Perrone F, Gridelli C.

    Lung Cancer. 2012 Jun;76(3):457-64. Epub 2012 Jan 31.

    PMID:
    22297086
    [PubMed - in process]
    2.

    Prognostic impact of the primary tumor location based on the hilar structures in non-small cell lung cancer with mediastinal lymph node metastasis.

    Ito M, Yamashita Y, Miyata Y, Ohara M, Tsutani Y, Ikeda T, Misumi K, Harada H, Omori K.

    Lung Cancer. 2012 Apr;76(1):93-7. Epub 2012 Jan 27.

    PMID:
    22285532
    [PubMed - in process]
    3.

    EGFR-TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment.

    Brugger W, Thomas M.

    Lung Cancer. 2012 Jan 24. [Epub ahead of print]

    PMID:
    22281074
    [PubMed - as supplied by publisher]
    4.

    Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses.

    Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

    Lung Cancer. 2012 Jun;76(3):478-85. Epub 2012 Jan 25.

    PMID:
    22277104
    [PubMed - in process]
    5.

    Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

    Gridelli C, de Marinis F, Di Maio M, Ardizzoni A, Belani CP, Cappuzzo F, Ciardiello F, Fidias P, Paz-Ares L, Perrone F, Pirker R, De Petris L, Stahel R.

    Lung Cancer. 2012 Jun;76(3):269-79. Epub 2012 Jan 21.

    PMID:
    22266040
    [PubMed - in process]
    6.

    In situ detection of lung cancer volatile fingerprints using bronchoscopic air-sampling.

    Santonico M, Lucantoni G, Pennazza G, Capuano R, Galluccio G, Roscioni C, La Delfa G, Consoli D, Martinelli E, Paolesse R, Di Natale C, D'Amico A.

    Lung Cancer. 2012 Jan 18. [Epub ahead of print]

    PMID:
    22264635
    [PubMed - as supplied by publisher]
    7.

    Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: In vitro and in vivo studies.

    Xue X, Sun DF, Sun CC, Liu HP, Yue B, Zhao CR, Lou HX, Qu XJ.

    Lung Cancer. 2012 Jun;76(3):300-8. Epub 2012 Jan 17.

    PMID:
    22261315
    [PubMed - in process]
    8.

    An ectopic ACTH-producing small cell lung carcinoma associated with enhanced corticosteroid biosynthesis in the peritumoral areas of adrenal metastasis.

    Satoh H, Saito R, Hisata S, Shiihara J, Taniuchi S, Nakamura Y, Nukiwa T, Ebina M, Sasano H.

    Lung Cancer. 2012 Jun;76(3):486-90. Epub 2012 Jan 16.

    PMID:
    22251774
    [PubMed - in process]
    9.

    Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.

    Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M; JO19907 Study Group.

    Lung Cancer. 2012 Jun;76(3):362-7. Epub 2012 Jan 14.

    PMID:
    22244743
    [PubMed - in process]
    10.

    Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.

    Ishikawa M, Miyahara R, Sonobe M, Horiuchi M, Mennju T, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N, Huang CL, Date H.

    Lung Cancer. 2012 Jun;76(3):431-8. Epub 2012 Jan 10.

    PMID:
    22236865
    [PubMed - in process]
    11.

    Challenges scoring radiation pneumonitis in patients irradiated for lung cancer.

    Yirmibesoglu E, Higginson DS, Fayda M, Rivera MP, Halle J, Rosenman J, Xie L, Marks LB.

    Lung Cancer. 2012 Jun;76(3):350-3. Epub 2012 Jan 9.

    PMID:
    22230037
    [PubMed - in process]
    12.

    History of tuberculosis as an independent prognostic factor for lung cancer survival.

    Heuvers ME, Aerts JG, Hegmans JP, Veltman JD, Uitterlinden AG, Ruiter R, Rodenburg EM, Hofman A, Bakker M, Hoogsteden HC, Stricker BH, van Klaveren RJ.

    Lung Cancer. 2012 Jun;76(3):452-6. Epub 2012 Jan 9.

    PMID:
    22226628
    [PubMed - in process]
    13.

    Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis.

    Cromwell I, van der Hoek K, Malfair Taylor SC, Melosky B, Peacock S.

    Lung Cancer. 2012 Jun;76(3):472-7. Epub 2012 Jan 9.

    PMID:
    22226627
    [PubMed - in process]
    14.

    A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer.

    Gao G, Chu H, Zhao L, Gui T, Xu Q, Shi J.

    Lung Cancer. 2012 Jun;76(3):380-6. Epub 2012 Jan 9.

    PMID:
    22226626
    [PubMed - in process]
    15.

    Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.

    O'Flaherty JD, Gray S, Richard D, Fennell D, O'Leary JJ, Blackhall FH, O'Byrne KJ.

    Lung Cancer. 2012 Apr;76(1):19-25. Epub 2011 Dec 29.

    PMID:
    22209049
    [PubMed - in process]
    17.

    Characteristics of lung cancer in women: Importance of hormonal and growth factors.

    Rouquette I, Lauwers-Cances V, Allera C, Brouchet L, Milia J, Nicaise Y, Laurent J, Delisle MB, Favre G, Didier A, Mazières J.

    Lung Cancer. 2012 Jun;76(3):280-5. Epub 2011 Dec 22.

    PMID:
    22197614
    [PubMed - in process]
    18.

    Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

    Massuti B, Cobo M, Camps C, Dómine M, Provencio M, Alberola V, Viñolas N, Rosell R, Tarón M, Gutiérrez-Calderón V, Lardelli P, Alfaro V, Nieto A, Isla D.

    Lung Cancer. 2012 Jun;76(3):354-61. Epub 2011 Dec 23.

    PMID:
    22197612
    [PubMed - in process]
    19.

    Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer.

    Baek JH, Kim H, Ahn JJ, Jegal Y, Seo KW, Ra SW, Park CR, Jung JP, Kim JW, Lee YJ, Cha HJ, Kwon WJ, Noh YJ, Oh S, Park JH, Min YJ.

    Lung Cancer. 2012 Jun;76(3):368-72. Epub 2011 Dec 20.

    PMID:
    22192919
    [PubMed - in process]
    20.

    CHD5, a tumor suppressor that is epigenetically silenced in lung cancer.

    Zhao R, Yan Q, Lv J, Huang H, Zheng W, Zhang B, Ma W.

    Lung Cancer. 2012 Jun;76(3):324-31. Epub 2011 Dec 18.

    PMID:
    22186629
    [PubMed - in process]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk